华丽家族股份有限公司独立董事 华丽家族股份有限公司（以下简称"公司"）于 2025 年 8 月 11 日收到上海 证券交易所（以下简称"上交所"）《关于对华丽家族股份有限公司增资收购股 权暨关联交易事项的监管工作函》（上证公函【2025】1211 号）（以下简称"《工 作函》"）。作为公司独立董事，我们根据中国证监会《上市公司独立董事管理 办法》《上海证券交易所股票上市规则》等法律法规及《公司章程》的相关规定， 本着勤勉尽责的原则，与管理层认真讨论了监管工作函的内容，基于独立判断的 立场，就《工作函》有关事项发表如下独立意见： 问题 2.关于资产评估。公告显示，本次评估采用资产基础法和市场法，资 产基础法评估增值率 347.70%-425.03%，市场法评估增值率 343.66%-441.06%, 最终选取资产基础法。请公司：（1）补充披露本次交易采用资产基础法评估的 具体情况，包括但不限于评估过程、主要参数、评估依据等，并说明标的评估 增值率较高的原因及合理性；（2）说明市场法评估的具体情况，包括但不限于 选取的可比上市公司、主要参数以及合理性；（3）结合问题（1）、（2）以及 同行业可比公司案例，说明最终 ...

证券代码：600503 证券简称：华丽家族 公告编号：临2025－022 华丽家族股份有限公司 关于上海证券交易所监管工作函的回复公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 华丽家族股份有限公司（以下简称"公司"或"华丽家族"）于近日收到上 海证券交易所下发的《关于对华丽家族股份有限公司增资收购股权暨关联交易 事项的监管工作函》（上证公函[2025] 1211号）（以下简称"《工作函》"），公司董 事会高度重视，并组织相关部门对《工作函》事项进行了分析及核查，现就《工 作函》回复如下： 问题 1.关于交易必要性。公告显示，海和药物主要从事肿瘤领域创新药物 的研发与生产。2024 年、2025 年 1-2 月，海和药物实现营业收入分别为 3.23 亿 元、7,682.37 万元，实现净利润分别为-2.09 亿元、-1,607.93 万元，截至目前尚 未实现盈利。上市公司主营业务为房地产开发，定期报告显示，2023 年、2024 年度公司实现营业收入分别为 1.61 亿元、3.53 亿元，净利润分别为 0.58 亿元、 ...

华丽家族股份有限公司公司拟进行增资所涉及的 上海海和药物研究开发股份有限公司股东全部权益价值 估值报告 金证估报字【2025】第 0097 号 (共一册,第一册) 金证（上海）资产评估有限公司 2025 年 08 月 08 日 品证(上海)资产评估有限公司 金证估报字【2025】第 0097 号 估值报告 目 景 | 声 | 99 | | --- | --- | | 摘 | . | | 正 | 7 manunuman manuman minumum minumum manuman manuman manuman mana | | | 委托人、被估值单位和其他估值报告使用人概况 | | | 估值目的 二、 | | | 三、 估值对象和估值范围 ……………………………………………………………………………………………………………… 10 | | | 价值类型 ………………………………………………………………………………………………………………………………………… 11 四、 | | | 估值基准日 五、 | | | 估值依据………………………………………………………………………………………………………………………… ...

华丽家族股份有限公司 关于召开2025年第一次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：600503 证券简称：华丽家族 公告编号：2025-024 (一)股东大会类型和届次 2025年第一次临时股东大会 (二)股东大会召集人：董事会 (三)投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的 方式 (五)网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 8 月 29 日 至2025 年 8 月 29 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过 互联网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 一、 召开会议的基本情况 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 8 月 29 日 14 点 30 分 召开地点：上海市松 ...

证券代码：600503 证券简称：华丽家族 公告编号：临2025－023 华丽家族股份有限公司 公司拟于 2025 年 8 月 29 日 14:30 在上海市松江区石湖荡镇三新公路 207 号会议室 召开 2025 年第一次临时股东大会。 详见公司于上交所网站（www.sse.com.cn）及指定媒体披露的《华丽家族股份有限 公司关于召开 2025 年第一次临时股东大会的通知》（公告编号：2025-024）。 （表决结果：8 票同意，0 票反对，0 票弃权） 第七届董事会第三十九次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 华丽家族股份有限公司（以下简称 "公司"）第七届董事会第三十九次会议于2025 年8月13日通过现场会议结合通讯表决的方式召开。会议通知于2025年8月8日以书面方 式送达全体董事。会议由董事长王伟林先生主持，会议应参加表决董事8人，实际参加 表决董事8人，公司高级管理人员列席了会议。本次会议的召集、召开及表决程序符合 《公司法》《公司章程》及《公司董事会议事规则》等有关规定。经与会董事审 ...

Group 1 - Multiple listed companies have announced plans to diversify into innovative pharmaceuticals this year, with Huayi Family planning to invest up to 300 million yuan in Shanghai Haihe Pharmaceutical Research and Development Co., Ltd. [1] - Shenlian Biopharmaceutical aims to expand from its existing animal vaccine business into the human innovative drug sector through acquisitions, having previously announced a 60 million yuan investment to acquire a 20.48% stake in Yangzhou Shizhiyuan Biotechnology Co., Ltd. [1][2] - The Chinese innovative drug market is experiencing rapid growth, with 43 innovative drugs approved in the first half of the year, a 59% year-on-year increase, and a projected total of 48 approvals for 2024 [2][3] Group 2 - Companies like Shenlian Biopharmaceutical are not only focused on financial returns but also on business synergies, leveraging their expertise in animal vaccines to enter the human drug market [3] - Huayi Family's investment in innovative drugs is seen as a strategic financial move, aiming for reasonable returns while exploring opportunities in emerging industries [2][3] - Traditional companies in mature industries are seeking new profit growth points through cross-industry diversification, which can aid in their transformation [3]

Investment Rating - The industry rating is optimistic, expecting overall returns to exceed the CSI 300 index by more than 5% in the next six months [11]. Core Insights - The report highlights that the real estate sector is experiencing a positive market trend, with the Shanghai Composite Index and Shenzhen Composite Index rising by 0.34% and 1.42% respectively on August 11, 2025. The Shenwan Real Estate Index increased by 1.24% [3]. - Specific developments include the planning adjustments in Shenzhen's Guangming District, which involve four residential land plots with varying land areas and floor area ratios [5]. - Guangzhou's state-owned enterprise, Zhujiang Real Estate, has initiated a price guarantee action for seven projects, promising to compensate buyers for price differences until the end of the year [6]. Market Performance - The top five performing stocks in the real estate sector include Shen Property A, Wantong Development, Tianbao Construction, Fuxing Shares, and Jintou City Development, with respective increases of 10.01%, 9.96%, 6.65%, 6.41%, and 6.01%. Conversely, the largest declines were seen in Rongfeng Holdings, Yatong Shares, Huali Family, Guangming Real Estate, and Shangshi Development, with decreases of -4.81%, -2.92%, -1.70%, -1.11%, and -1.04% [4]. Company Announcements - Huazhong City Holdings announced a suspension of trading due to a court-ordered liquidation [9]. - Zhuhai Huafa Industrial Co., Ltd. adjusted the coupon rate of its corporate bonds from 3.90% to 2.30%, with a total issuance of 2 billion yuan and a maturity of five years [9]. Industry News - The Shenzhen Intermediate People's Court announced the auction of the Shenzhen Huangting Plaza, with an estimated value of 4.361 billion yuan and a starting price of approximately 3.053 billion yuan [8].

Group 1 - Huayi Family Co., Ltd. plans to invest up to 300 million yuan in Shanghai Haihe Pharmaceutical Research and Development Co., Ltd. through a share placement at a price of 4.75 yuan per share, acquiring no more than 63.157895 million shares [2] - After the investment, Huayi Family is expected to hold between 5% and 8.09% of Haihe Pharmaceutical's shares, with its controlling shareholder holding approximately 11.54% of Haihe Pharmaceutical's shares [2] - Haihe Pharmaceutical, established in 2011, focuses on the discovery, development, production, and commercialization of innovative drugs in the oncology field, with three products already commercialized and five in clinical research [2] Group 2 - The investment is seen as a strategic financial investment based on the long-term development potential of innovative drugs, aiming to achieve reasonable financial returns while ensuring stable operations of Huayi Family's main business [3] - The innovative drug market has been rapidly developing, with many pharmaceutical companies achieving significant economic benefits through research and development [3] - Huayi Family aims to explore opportunities in emerging industries through this investment in Haihe Pharmaceutical [3]

Core Viewpoint - The company Huayi Family (600503.SH) plans to invest up to 300 million yuan in Haihe Pharmaceutical's share placement financing, aiming to acquire shares at a price of 4.75 yuan per share, totaling no more than 63.157895 million shares [1] Summary by Relevant Sections - Investment Details - The company intends to participate in Haihe Pharmaceutical's financing with a maximum investment of 300 million yuan [1] - The share price for the new shares is set at 4.75 yuan, allowing for the acquisition of up to 63.157895 million shares [1] - Ownership Implications - Post-investment, the company's ownership stake in Haihe Pharmaceutical is expected to be between 5% and 8.09% [1] - Strategic Objectives - The purpose of this capital increase is to ensure stable operations of the main business while seeking reasonable financial returns [1] - The investment also aims to explore opportunities in emerging industries and development prospects [1]

Group 1 - The company plans to invest up to 300 million yuan in Shanghai Haihe Pharmaceutical Research and Development Co., Ltd. through a share placement, acquiring up to 63.157895 million new shares at a price of 4.75 yuan per share [1] - After the investment, the company's ownership stake in Haihe Pharmaceutical is expected to be between 5% and 8.09% [1] - Haihe Pharmaceutical focuses on the discovery, development, production, and commercialization of innovative drugs in the oncology field, with three products already launched in China and Japan, and five products in clinical research [1] Group 2 - This capital increase is a strategic financial investment reflecting the company's positive outlook on the long-term development potential of innovative drugs, aiming to ensure stable operations while seeking reasonable financial returns and exploring opportunities in emerging industries [2]